Your browser is old and is not supported. Upgrade for better security.


Platform drugs for orphan diseases like Cancer and Ebola

What Friends Say

In the news

FDA Grants Orphan Drug Designation to OS2966 in the Treatment of Ovarian Cancer
January 21, 2015
ncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for OS2966 in the treatment of ovarian cancer. The investigational drug candidate also received orphan designation for glioblastoma last summer.
Thomas W. Geisbert
August 23, 2014
Thomas W. Geisbert is a virologist who specializes in viral hemorrhagic fevers such as the Ebola virus. He and his team at the University of Texas Medical Branch in Galveston are currently working on developing vaccines to treat these diseases, which have mortality rates as high as 90 percent.
Ebola finds a new foe in crowd-funded startup
August 22, 2014
Yet San Francisco-based OncoSynergy, created after founder Dr. Shawn Carbonell dropped out of neuroscience residency at Cedars-Sinai Medical Center in Los Angeles, might have an inroad to a potential ebola treatment. Its experimental cancer drug, called OS-2966, is thought to inhibit a protein that is fundamental for progression of aggressive tumors like brain and ovarian cancer and, the company said, appears to be hijacked by the ebola virus during infection.
Science Exchange Stories: OncoSynergy, fighting brain cancer as the family business
January 21, 2014
To put it in his words, “When I found out she was single and was no longer in neurosurgery I made it my mission to both marry her and hire her. Last month both became reality.”
CMC Biologics, OncoSynergy Make Pact to Develop Materials for Toxicology Studies
December 17, 2013
CMC Biologics has inked an agreement with biotech start-up OncoSynergy to develop cell lines and for process development, analytical development, and manufacturing of both non-GMP material for early toxicology testing and cGMP material for IND-enabling toxicology studies and Phase I clinical trials. This work, the firms say, will advance OncoSynergy's OS2966 mAb program.
Science Exchange Stories: Shawn Carbonell, Brain Surgery Dropout
November 13, 2013
Although he had spent the last 18 years prepping for a career as an academic neurosurgeon, he couldn’t stop thinking about an idea he had that could help fight cancer. He had many options available to him, but he risked it all because he wanted to get a drug to the clinic in the quickest way possible.
What People Say